HomeCompareGNFTF vs EPRT

GNFTF vs EPRT: Dividend Comparison 2026

GNFTF yields 19.18% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNFTF wins by $6.0K in total portfolio value
10 years
GNFTF
GNFTF
● Live price
19.18%
Share price
$10.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$6,165.13
Full GNFTF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GNFTF vs EPRT

📍 GNFTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFTF
Annual income on $10K today (after 15% tax)
$1,629.91/yr
After 10yr DRIP, annual income (after tax)
$5,240.36/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $5,674.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFTF + EPRT for your $10,000?

GNFTF: 50%EPRT: 50%
100% EPRT50/50100% GNFTF
Portfolio after 10yr
$66.4K
Annual income
$9,502.93/yr
Blended yield
14.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GNFTF
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
0.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFTF buys
0
EPRT buys
0
No recent congressional trades found for GNFTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTFEPRT
Forward yield19.18%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$69.4K$63.4K
Annual income after 10y$6,165.13$12,840.73
Total dividends collected$38.6K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: GNFTF vs EPRT ($10,000, DRIP)

YearGNFTF PortfolioGNFTF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$12,618$1,917.55$11,205$505.18+$1.4KGNFTF
2$15,762$2,261.19$12,672$682.46+$3.1KGNFTF
3$19,505$2,639.91$14,490$930.48+$5.0KGNFTF
4$23,924$3,053.13$16,786$1,282.69+$7.1KGNFTF
5$29,098$3,499.76$19,753$1,791.56+$9.3KGNFTF
6$35,113$3,978.25$23,677$2,541.64+$11.4KGNFTF
7$42,058$4,486.56$29,008$3,672.99+$13.1KGNFTF
8$50,024$5,022.33$36,463$5,425.08+$13.6KGNFTF
9$59,109$5,582.83$47,238$8,221.57+$11.9KGNFTF
10$69,411$6,165.13$63,385$12,840.73+$6.0KGNFTF

GNFTF vs EPRT: Complete Analysis 2026

GNFTFStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GNFTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFTF vs SCHDGNFTF vs JEPIGNFTF vs OGNFTF vs KOGNFTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.